Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $5.9 million.

  • Fennec Pharmaceuticals' Accounts Payables rose 5169.38% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 5169.38%. This contributed to the annual value of $3.2 million for FY2024, which is 1421.39% down from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Accounts Payables of $5.9 million as of Q3 2025, which was up 5169.38% from $5.9 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Accounts Payables ranged from a high of $5.9 million in Q2 2025 and a low of $677000.0 during Q2 2021
  • Its 5-year average for Accounts Payables is $3.3 million, with a median of $3.0 million in 2023.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Accounts Payables plummeted by 7542.65% in 2021, and later surged by 15745.94% in 2022.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Accounts Payables stood at $1.2 million in 2021, then soared by 107.11% to $2.4 million in 2022, then skyrocketed by 58.08% to $3.8 million in 2023, then decreased by 14.21% to $3.2 million in 2024, then surged by 80.99% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $5.9 million for Q2 2025, and $5.3 million during Q1 2025.